Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at th
Go back to Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at th| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 12.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.20 | 52 Week High | $7.95 | |||
| Open | $12.20 | 52 Week Low | $0.40 | |||
| Day High | $12.20 | P/E | N/A | |||
| Day Low | $12.20 | EPS | $-5.33 | |||
| Volume | 78 | |||||
